Now showing items 1-3 of 3
-
Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway
Łosińska, Katarzyna Weronika; Pripp, Are Hugo; Bakland, Gunnstein; Fevang, Bjørg Tilde Svanes; Brekke, Lene Kristin; Wierød, Ada; Korkosz, Mariusz; Haugeberg, Glenn (Arthritis care & research;, Peer reviewed; Journal article, 2024)Objective. We aim to compare drug effectiveness and persistence between the reference etanercept (ETN) and ETN biosimilar SB4 in patients with psoriatic arthritis (PsA) naive to ETN and to investigate drug effectiveness ... -
Effectiveness and Persistence in SB4- and Reference Etanercept–Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway
Haugeberg, Glenn; Bakland, Gunnstein; Rødevand, Erik; Hansen, Inger Johanne Widding; Diamantopoulos, Andreas P; Pripp, Are Hugo (Peer reviewed; Journal article, 2023)Objective Biosimilars represent cost-effective alternatives to reference biologic disease-modifying antirheumatic drugs. Our objective was to compare drug effectiveness and drug persistence in the treatment of rheumatoid ... -
No deterioration in health-related quality of life in patients with axial spondyloarthritis followed for 5 years in ordinary outpatient clinics in the biological treatment era.
Rohde, Gudrun E.; Berg, Kari Ellen; Pripp, Are Hugo; Prøven, Anne; Haugeberg, Glenn (Quality of Life Research;January 2020, Volume 29, Issue 1, Journal article; Peer reviewed, 2019-09-17)Background Axial spondyloarthritis (ax-SpA) causes pain, fatigue, stiffness, loss of physical function and impaired healthrelated quality of life (HRQOL). Aims The study aimed to explore the changes in HRQOL over 5 years ...